It constitutes an alternative, promising anti-CD33 immunotherapeutic approach that further builds on the clinical approval of anti-CD19 CAR T cells (Kymriah) to treat B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma [43]. The gene discussed is CD33; the disease is non-Hodgkin lymphoma.